SmartTab Competitors

Velesco applies nimblocity to your early stage drug development projects, with our proven formulation of expertise, flexibility, dedication, and velocity to clinic. Expertise and experience Velesco is a CMC contract research organization, founded and staffed by pharmaceutical scientists from Pfizer's former Michigan R&D campus. Our team has experience with more than 100 drug development programs. Flexibility Our nimble processes and focused expertise enables us to overcome even the most challenging obstacles. Our team is responsive, accommodating, and eager to help you reach the full potential of your compound, quickly and efficiently. Personalized Partnerships We treat your project like it's our own and share everything from insightful observations to solutions for problematic analytic methods, to assistance with the FDA registration process. All our services are royalty-free. Velocity to clinic We're committed to getting your compound to the clinic on time. Our size, capacity, and expertise allow us to accommodate changes swiftly while maintaining control and quality. As experts in pharmaceutical analytical chemistry, drug formulation development, and cGMP clinical supply manufacture, Velesco scientists have a proven track record of moving compounds through the critical drug development process with nimblocity and unrivaled success.

Private biotech company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types.

4P Therapeutics develops new transdermal products that meet the needs of patients, physicians, and payers. 4P Therapeutics is a product research and development company with expertise in technology development, drug formulation, product design, and preclinical & clinical development. 4P is not dependent on a specific platform technology but instead evaluates multiple different transdermal technology and formulation approaches to find the right match for a particular drug or biologic product being developed. Our in-house capabilities allow us to work with proven preclinical models either in vitro or in vivo and have the capability to move quickly to the clinic with a technology and formulation tailored for each specific transdermal product. We believe that the keys to success in the novel transdermal space are having the freedom to choose from multiple technologies and not be burdened with a one-size-fits-all platform technology as well as having world-class experience in transdermal formulation and product development. Current industry dynamics for transdermal product development and commercialization have lead us to create a business model for 4P that takes advantage of our own proprietary technology as well as the freedom to operate with multiple technologies. 4P has built an infrastructure that allows our experienced team to go from concept to proof-of-concept in humans in our Atlanta, GA, facility. The 4P Therapeutics team is experienced in developing a broad range of drug deliver technologies, particularly novel transdermal technologies for compounds that are currently injected or administered by SC or IV infusion. The company's team also offers experience with developing vaccines, medical devices, and diagnostics.